Abstract:The active form of vitamin D3, 1,25-dihydroxyvitamin D3, is a major regulator of bone and calcium homeostasis. In addition, this hormone also inhibits the proliferation and stimulates the differentiation of normal as well as malignant cells. Supraphysiological doses of 1,25-dihydroxyvitamin D3 are required to reduce cancer cell proliferation. However, these doses will lead in vivo to calcemic side effects such as hypercalcemia and hypercalciuria. During the last 25 years, many structural analogs of 1,25-dihydroxyvitamin D3 have been synthesized by the introduction of chemical modifications in the A-ring, central CD-ring region or side chain of 1,25-dihydroxyvitamin D3 in the hope to find molecules with a clear dissociation between the beneficial antiproliferative effects and adverse calcemic side effects. One example of such an analog with a good dissociation ratio is calcipotriol (Daivonex®), which is clinically used to treat the hyperproliferative skin disease psoriasis. Other vitamin D analogs were clinically approved for the treatment of osteoporosis or secondary hyperparathyroidism. No vitamin D analog is currently used in the clinic for the treatment of cancer although several analogs have been shown to be potent drugs in animal models of cancer. Transcriptomics studies as well as in vitro cell biological experiments unraveled basic mechanisms involved in the antineoplastic effects of vitamin D and its analogs. 1,25-dihydroxyvitamin D3 and analogs act in a cell type- and tissue-specific manner. Moreover, a blockade in the transition of the G0/1 toward S phase of the cell cycle, induction of apoptosis, inhibition of migration and invasion of tumor cells together with effects on angiogenesis and inflammation have been implicated in the pleiotropic effects of 1,25-dihydroxyvitamin D3 and its analogs. In this review we will give an overview of the action of vitamin D analogs in tumor cells and look forward how these compounds could be introduced in the clinical practice.

Design, synthesis and biological evaluation of nonsecosteroidal vitamin D3 receptor ligands as anti-tumor agents

Novel Nonsecosteroidal VDR Ligands with Phenyl-Pyrrolyl Pentane Skeleton for Cancer Therapy

Further Developments of the Phenyl-Pyrrolyl Pentane Series of Nonsteroidal Vitamin D Receptor Modulators As Anticancer Agents

Design and Synthesis of Novel Dehydroepiandrosterone Analogues As Potent Antiproliferative Agents

Sulfonyl-containing Phenyl-Pyrrolyl Pentane Analogues: Novel Non-Secosteroidal Vitamin D Receptor Modulators with Favorable Physicochemical Properties, Pharmacokinetic Properties and Anti-Tumor Activity.

Vitamin D and its analogs as anticancer and anti-inflammatory agents

Synthesis and biological evaluation of 1α,25-dihydroxyvitamin D3 analogues with aromatic side chains attached at C-17.

Structure and the Anticancer Activity of Vitamin D Receptor Agonists

Design, synthesis, and biological activity of D-bishomo-1α,25-dihydroxyvitamin D 3 analogs and their crystal structures with the vitamin D nuclear receptor

Discovery of Novel Nonsteroidal VDR Agonists with Novel Diarylmethane Skeleton for the Treatment of Breast Cancer.

Synthesis and in Vitro Bioiogicai Activity of 3-Phenyi-3-pyrroiyipentane Deriva-Tives

Novel vitamin D analogs as potential therapeutics: metabolism, toxicity profiling, and antiproliferative activity.

Novel nonsecosteroidal VDR agonists with phenyl-pyrrolyl pentane skeleton.

The future of vitamin D analogs

Investigation of 20S-Hydroxyvitamin D3 Analogs and Their 1Α-Oh Derivatives As Potent Vitamin D Receptor Agonists with Anti-Inflammatory Activities

New vitamin D analogs as potential therapeutics in melanoma

Design, Synthesis and Biological Activities of Novel Gemini 20S-Hydroxyvitamin D3 Analogs.

Vitamin D analogues: Potential use in cancer treatment

Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton

Design, Synthesis and Biological Evaluation of a Series of New Resveratrol Analogues As Potential Anti-Cancer Agents

Selective vitamin D receptor modulators and their effects on colorectal tumor growth